HIV Treatment Bulletin Volume 6 Number 9 September 2005

Special Issue: Reports from 3rd IAS Conference on HIV Pathogenesis and Treatment

EDITORIAL

CONFERENCE REPORT

• 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27July 2005, Rio de Janeiro, Brasil

RIO: TRANSMISSION

• Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

RIO: PMTCT

• Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

RIO: PREGNANCY

• New drugs in pregnancy: atazanavir; T20

RIO: PAEDIATRICS

• Lopinavir/r use in children less than two years old – promising results despite low plasma levels
• Favourable outcomes in children treated with HAART in the MSF programmes
• Encouraging results with cut up generic fixed dose combination tablets in Uganda
• Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

RIO: ANTIRETROVIRALS

• Benefit of maintaining M184V with 3TC monotherapy: final 48-week results
• T20 (enfuvirtide) studies presented at Rio
• Strategies for salvage therapy
• Antiviral activity of foscarnet in salvage patients
• Novel strategies with existing drugs: Reduced PI combination of indinavir/ritonavir 400/100 in Mali; 5 Days On HAART, 2 Days off; Kaletra monotherapy
• Antiretroviral activity of new and novel agents

RIO: PHARMACOLOGY AND DRUG INTERACTIONS

• Overview of pharmacology studies
• Tenofovir interactions and renal toxicity
• Atazanavir inter-patient variability and drug interactions
• Interactions between proton pump inhibitors and PIs
• PK in pregnancy and liver impairment
• Drug interactions with new and existing drugs
• PK in paediatric patients

RIO: TB COINFECTION

• Incidence of TB infection despite HAART and treatment in coinfected patients
• Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

RIO: TREATMENT ACCESS

• Does WHO clinical stage reliably predict who should receive ARV treatment?
• Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study

TREATMENT ACCESS

• UK to increase Global Fund commitment to $175M annually in 2006, 2007

TREATMENT GUIDELINES

• UK treatment guidelines 2005 online

REGULATORY ISSUES & SIDE EFFECTS

• Statements from the CHMP/EMEA:
1. on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients
2. on the use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection

PREGNANCY AND PMTCT

• US Preventative Services Task Force recommends screening all pregnant women for HIV

ON THE WEB

• Conference reports
• Community newsletters and journals
• Community resources

MEETING ANNOUNCEMENTS

PUBLICATIONS AND SERVICES FROM i-BASE